Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akero Therapeutics stock

Own Akero Therapeutics stock in just a few minutes.

Akero Therapeutics, Inc is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Akero Therapeutics employs 21 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Akero Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AKRO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Akero Therapeutics share price

Use our graph to track the performance of AKRO stocks over time.

Akero Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$19.58 - $41.16
50-day moving average $29.74
200-day moving average $28.96
Wall St. target price$60.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-91.75

Buy Akero Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akero Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akero Therapeutics financials

Gross profit TTM $0
Return on assets TTM -24.35%
Return on equity TTM -40.89%
Profit margin 0%
Book value $7.45
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Akero Therapeutics shares

There are currently 3.3 million Akero Therapeutics shares held short by investors – that's known as Akero Therapeutics's "short interest". This figure is 15.6% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Akero Therapeutics shares can be evaluated.

Akero Therapeutics's "short interest ratio" (SIR)

Akero Therapeutics's "short interest ratio" (SIR) is the quantity of Akero Therapeutics shares currently shorted divided by the average quantity of Akero Therapeutics shares traded daily (recently around 300954.39709882). Akero Therapeutics's SIR currently stands at 11.03. In other words for every 100,000 Akero Therapeutics shares traded daily on the market, roughly 11030 shares are currently held short.

However Akero Therapeutics's short interest can also be evaluated against the total number of Akero Therapeutics shares, or, against the total number of tradable Akero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akero Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Akero Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1739% of the tradable shares (for every 100,000 tradable Akero Therapeutics shares, roughly 174 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akero Therapeutics.

Find out more about how you can short Akero Therapeutics stock.

Akero Therapeutics share dividends

We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.

Akero Therapeutics overview

Akero Therapeutics, Inc. , a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site